CCI Approves Torrent Pharma’s Acquisition of J. B. Chemicals & Pharmaceuticals with Voluntary Modifications

The Competition Commission of India (CCI) has approved Torrent Pharmaceuticals Limited’s proposed acquisition of J. B. Chemicals & Pharmaceuticals Limited, subject to voluntary modifications offered by the parties. 

The transaction involves Torrent Pharma acquiring a controlling stake in J. B. Chemicals, followed by the amalgamation of the target company with Torrent Pharma. This strategic acquisition aims to enhance Torrent Pharma’s position in the Indian pharmaceutical sector.

Details of the Proposed Combination

Torrent Pharmaceuticals Limited, the acquirer, is the flagship company of the Torrent Group and operates in the manufacturing and sale of pharmaceutical formulations (FDFs) across multiple therapeutic categories. 

J.B. Chemicals & Pharmaceuticals Limited, the target company, is engaged in the manufacturing and marketing of a wide range of formulations and active pharmaceutical ingredients (APIs), besides offering Contract Development and Manufacturing Organisation (CDMO) services. 

The acquisition will bring synergies in product development, distribution, and research capabilities for the combined entity.

Official Confirmation from Torrent Pharma

In its official statement, Torrent Pharma confirmed that the CCI granted approval for the transaction on October 21, 2025. This follows earlier announcements made through media releases and stock exchange intimations dated June 29, July 3, and September 23, 2025. The approval is conditional upon compliance with voluntary modifications outlined in the CCI’s final order.

Torrent Pharma Share Price Performance

On October 23, 2025, Torrent Pharma share price opened at ₹3,572.00, touching the day’s high at ₹3,617.30, as of 11:07 AM on the NSE.

Also Read: Torrent Pharmaceuticals to Acquire 26% Stake in Hybrid Power Project! 

Conclusion

The CCI’s clearance marks a major milestone for Torrent Pharma’s acquisition of J. B. Chemicals, paving the way for further integration once regulatory conditions are fulfilled. The move is expected to strengthen Torrent Pharma’s market presence and expand its portfolio across therapeutic and geographic segments.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.